Skip to main content
Top
Published in: Angiogenesis 3/2008

Open Access 01-09-2008 | Original Paper

Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne®), in the CAM model

Authors: E. Debefve, B. Pegaz, H. van den Bergh, G. Wagnières, N. Lange, J.-P. Ballini

Published in: Angiogenesis | Issue 3/2008

Login to get access

Abstract

The aim of the present study was to monitor photodynamic angioocclusion with verteporfin in capillaries. Details of this process were recorded under a microscope in real-time using a high-sensitivity video camera. A procedure was developed based on intravenous (i.v.) injection of a light-activated drug, Visudyne®, into the chorioallantoic membrane (CAM) of a 12-day-old chicken embryo. The effect of light activation was probed after 24 h by i.v. injection of a fluorescent dye (FITC dextran), and analysis of its fluorescence distribution. The angioocclusive effect was graded based on the size of the occluded vessels, and these results were compared with clinical observations. The time-resolved thrombus formation taking place in a fraction of the field of view was video recorded using a Peltier-cooled CCD camera. This vessel occlusion in the CAM model was reproducible and, in many ways, similar to that observed in the clinical use of verteporfin. The real-time video recording permitted the monitoring of platelet aggregation and revealed size-selective vascular closure as well as some degree of vasoconstriction. Platelets accumulated at intravascular junctions within seconds after verteporfin light activation, and capillaries were found to be closed 15 min later at the applied conditions. Larger-diameter vessels remained patent. Repetition of these data with a much more sensitive camera revealed occlusion of the treated area after 5 min with doses of verteporfin and light similar to those used clinically. Consequently, newly developed light-activated drugs can now be studied under clinically relevant conditions.
Literature
1.
go back to reference Rubin GS, Roche KB, Prasada-Rao P, Fried LP (1994) Visual impairment and disability in older adults. Optom Vis Sci 71:750–760PubMedCrossRef Rubin GS, Roche KB, Prasada-Rao P, Fried LP (1994) Visual impairment and disability in older adults. Optom Vis Sci 71:750–760PubMedCrossRef
2.
go back to reference Ciulla TA, Danis RP, Harris A (1998) Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 43:134–146PubMedCrossRef Ciulla TA, Danis RP, Harris A (1998) Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 43:134–146PubMedCrossRef
3.
go back to reference Macular photocoagulation study group (1994) Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112:480–488 Macular photocoagulation study group (1994) Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112:480–488
4.
go back to reference Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 117:1329–1345 Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 117:1329–1345
5.
go back to reference Verteporfin in photodynamic therapy (VIP) study group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRef Verteporfin in photodynamic therapy (VIP) study group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRef
6.
go back to reference Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 119:198–207 Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Arch Ophthalmol 119:198–207
7.
go back to reference Verteporfin in photodynamic therapy (VIP) study group (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no. 3. Ophthalmology 110:667–673CrossRef Verteporfin in photodynamic therapy (VIP) study group (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP report no. 3. Ophthalmology 110:667–673CrossRef
8.
go back to reference Van den Bergh H, Ballini J-P (2003) Photodynamic therapy: basic principles and mechanisms. In: Frankhauser F, Kwasniewska S (eds) Lasers in ophthalmology—basic, diagnostic and surgical aspects. A review. Kugler Publications, The Hague, The Netherland Van den Bergh H, Ballini J-P (2003) Photodynamic therapy: basic principles and mechanisms. In: Frankhauser F, Kwasniewska S (eds) Lasers in ophthalmology—basic, diagnostic and surgical aspects. A review. Kugler Publications, The Hague, The Netherland
9.
go back to reference Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323–328PubMed Fingar VH (1996) Vascular effects of photodynamic therapy. J Clin Laser Med Surg 14:323–328PubMed
10.
go back to reference Mellish KJ, Brown SB (2001) Verteporfin: a milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother 2:351–361PubMedCrossRef Mellish KJ, Brown SB (2001) Verteporfin: a milestone in opthalmology and photodynamic therapy. Expert Opin Pharmacother 2:351–361PubMedCrossRef
11.
go back to reference Schmidt U, Birngruber R, Hasan T (1992) Selective occlusion of ocular neovascularization by photodynamic therapy. Ophthalmologe 89:391–394PubMed Schmidt U, Birngruber R, Hasan T (1992) Selective occlusion of ocular neovascularization by photodynamic therapy. Ophthalmologe 89:391–394PubMed
12.
go back to reference Schmidt-Erfurth U, Hasan T, Gragoudas E et al (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953–1961PubMed Schmidt-Erfurth U, Hasan T, Gragoudas E et al (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953–1961PubMed
13.
14.
go back to reference Miller H, Miller B (1993) Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 111:855–860PubMed Miller H, Miller B (1993) Photodynamic therapy of subretinal neovascularization in the monkey eye. Arch Ophthalmol 111:855–860PubMed
15.
go back to reference Miller JW, Walsh AW, Kramer M et al (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113:810–818PubMed Miller JW, Walsh AW, Kramer M et al (1995) Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 113:810–818PubMed
16.
go back to reference Van den Bergh H, Ballini JP, Sickenberg M (2004) On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. J Fr Ophtalmol 27:75–78 Van den Bergh H, Ballini JP, Sickenberg M (2004) On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration. J Fr Ophtalmol 27:75–78
17.
go back to reference Ben Hur E, Heldman E, Crane SW, Rosenthal I (1988) Release of clotting factors from photosensitized endothelial cells: a possible trigger for blood vessel occlusion by photodynamic therapy. FEBS Lett 236:105–108PubMedCrossRef Ben Hur E, Heldman E, Crane SW, Rosenthal I (1988) Release of clotting factors from photosensitized endothelial cells: a possible trigger for blood vessel occlusion by photodynamic therapy. FEBS Lett 236:105–108PubMedCrossRef
18.
go back to reference Schuster A, Oishi H, Beny JL, Stergiopulos N, Meister JJ (2001) Simultaneous arterial calcium dynamics and diameter measurements: application to myoendothelial communication. Am J Physiol Heart Circ Physiol 280:H1088–H1096PubMed Schuster A, Oishi H, Beny JL, Stergiopulos N, Meister JJ (2001) Simultaneous arterial calcium dynamics and diameter measurements: application to myoendothelial communication. Am J Physiol Heart Circ Physiol 280:H1088–H1096PubMed
19.
go back to reference West CM, West DC, Kumar S, Moore JV (1990) A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int J Radiat Biol 58:145–156PubMedCrossRef West CM, West DC, Kumar S, Moore JV (1990) A comparison of the sensitivity to photodynamic treatment of endothelial and tumour cells in different proliferative states. Int J Radiat Biol 58:145–156PubMedCrossRef
20.
go back to reference Schneckenburger H, Ruck A, Bartos B, Steiner R (1988) Intracellular distribution of photosensitizing porphyrins measured by video-enhanced fluorescence microscopy. J Photochem Photobiol B 2:355–363PubMedCrossRef Schneckenburger H, Ruck A, Bartos B, Steiner R (1988) Intracellular distribution of photosensitizing porphyrins measured by video-enhanced fluorescence microscopy. J Photochem Photobiol B 2:355–363PubMedCrossRef
21.
go back to reference Foster TH, Primavera MC, Marder VJ, Hilf R, Sporn LA (1991) Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res 51:3261–3266PubMed Foster TH, Primavera MC, Marder VJ, Hilf R, Sporn LA (1991) Photosensitized release of von Willebrand factor from cultured human endothelial cells. Cancer Res 51:3261–3266PubMed
22.
go back to reference Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C et al (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480PubMedCrossRef Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C et al (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480PubMedCrossRef
23.
go back to reference Andre P, Denis CV, Ware J et al (2000) Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 96:3322–3328PubMed Andre P, Denis CV, Ware J et al (2000) Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 96:3322–3328PubMed
24.
go back to reference Schmidt-Erfurth U, Hasan T (2000) Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45:195–214PubMedCrossRef Schmidt-Erfurth U, Hasan T (2000) Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45:195–214PubMedCrossRef
25.
go back to reference Augustin AJ, Offermann I (2006) Emerging drugs for age-related macular degeneration. Expert Opin Emerg Drugs 11:725–740PubMedCrossRef Augustin AJ, Offermann I (2006) Emerging drugs for age-related macular degeneration. Expert Opin Emerg Drugs 11:725–740PubMedCrossRef
26.
go back to reference Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRef Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRef
27.
go back to reference Lange N, Ballini JP, Wagnieres G, van den Bergh H (2001) A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest Ophthalmol Vis Sci 42:38–46PubMed Lange N, Ballini JP, Wagnieres G, van den Bergh H (2001) A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest Ophthalmol Vis Sci 42:38–46PubMed
28.
go back to reference Romanoff AL (1967) Biochemistry of the avian embryo: a quantitative analysis of prenatal development. Interscience, New York Romanoff AL (1967) Biochemistry of the avian embryo: a quantitative analysis of prenatal development. Interscience, New York
29.
go back to reference Kaiser PK (2006) Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension—TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132–1142PubMedCrossRef Kaiser PK (2006) Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension—TAP report no. 8. Graefes Arch Clin Exp Ophthalmol 244:1132–1142PubMedCrossRef
30.
go back to reference Sickenberg M, Ballini JP, van den Bergh H (2004) [Visudyne photodynamic therapy and feeder vessel occlusion: rationale of a synergistic association and clinical options]. J Fr Ophtalmol 27:93–102PubMedCrossRef Sickenberg M, Ballini JP, van den Bergh H (2004) [Visudyne photodynamic therapy and feeder vessel occlusion: rationale of a synergistic association and clinical options]. J Fr Ophtalmol 27:93–102PubMedCrossRef
31.
go back to reference Rubin GS, Bressler NM (2002) Effects of verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) Investigation—TAP report no. 4. Retina 22:536–544PubMedCrossRef Rubin GS, Bressler NM (2002) Effects of verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) Investigation—TAP report no. 4. Retina 22:536–544PubMedCrossRef
32.
go back to reference Mones J, Rubin GS (2005) Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye 19:1142–1150PubMedCrossRef Mones J, Rubin GS (2005) Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration. Eye 19:1142–1150PubMedCrossRef
33.
go back to reference Schmidt-Erfurth U, Bauman W, Gragoudas E et al (1994) Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101:89–99PubMed Schmidt-Erfurth U, Bauman W, Gragoudas E et al (1994) Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. Ophthalmology 101:89–99PubMed
34.
go back to reference Schmidt-Erfurth U, Flotte TJ, Gragoudas ES et al (1996) Benzoporphyrin–lipoprotein-mediated photodestruction of intraocular tumors. Exp Eye Res 62:1–10PubMedCrossRef Schmidt-Erfurth U, Flotte TJ, Gragoudas ES et al (1996) Benzoporphyrin–lipoprotein-mediated photodestruction of intraocular tumors. Exp Eye Res 62:1–10PubMedCrossRef
35.
go back to reference Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Birngruber R (1995) In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 17:178–188PubMedCrossRef Schmidt-Erfurth U, Hasan T, Schomacker K, Flotte T, Birngruber R (1995) In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 17:178–188PubMedCrossRef
36.
go back to reference Kramer M, Miller JW, Michaud N et al (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438PubMed Kramer M, Miller JW, Michaud N et al (1996) Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 103:427–438PubMed
37.
go back to reference Husain D, Miller JW, Michaud N et al (1996) Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114:978–985PubMed Husain D, Miller JW, Michaud N et al (1996) Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 114:978–985PubMed
38.
go back to reference Lin SC, Lin CP, Feld JR, Duker JS, Puliafito CA (1994) The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res 13:513–522PubMedCrossRef Lin SC, Lin CP, Feld JR, Duker JS, Puliafito CA (1994) The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res 13:513–522PubMedCrossRef
39.
go back to reference Schmidt-Erfurth U, Miller J, Sickenberg M et al (1998) Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 236:365–374PubMedCrossRef Schmidt-Erfurth U, Miller J, Sickenberg M et al (1998) Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 236:365–374PubMedCrossRef
40.
go back to reference Miller JW, Schmidt-Erfurth U, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161–1173PubMed Miller JW, Schmidt-Erfurth U, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161–1173PubMed
41.
go back to reference Schlotzer-Schrehardt U, Viestenz A, Naumann GO et al (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757PubMedCrossRef Schlotzer-Schrehardt U, Viestenz A, Naumann GO et al (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 240:748–757PubMedCrossRef
42.
go back to reference Gelisken F, Lafaut BA, Inhoffen W et al (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207–211PubMedCrossRef Gelisken F, Lafaut BA, Inhoffen W et al (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207–211PubMedCrossRef
43.
go back to reference Recchia FM, Greenbaum S, Recchia CA et al (2006) Self-reported acute decrease in visual acuity after photodynamic therapy for age-related macular degeneration. Retina 26:1042–1048PubMedCrossRef Recchia FM, Greenbaum S, Recchia CA et al (2006) Self-reported acute decrease in visual acuity after photodynamic therapy for age-related macular degeneration. Retina 26:1042–1048PubMedCrossRef
44.
go back to reference Cardillo PF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23:752–763CrossRef Cardillo PF, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23:752–763CrossRef
45.
go back to reference Hammer-Wilson MJ, Akian L, Espinoza J, Kimel S, Berns MW (1999) Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers. J Photochem Photobiol B 53:44–52PubMedCrossRef Hammer-Wilson MJ, Akian L, Espinoza J, Kimel S, Berns MW (1999) Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers. J Photochem Photobiol B 53:44–52PubMedCrossRef
46.
go back to reference Vargas A, Pegaz B, Debefve E et al (2004) Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int J Pharm 286:131–145PubMedCrossRef Vargas A, Pegaz B, Debefve E et al (2004) Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int J Pharm 286:131–145PubMedCrossRef
47.
go back to reference Pegaz B, Debefve E, Borle F et al (2005) Encapsulation of porphyrins and chlorins in biodegradable nanoparticles: the effect of dye lipophilicity on the extravasation and the photothrombic activity. A comparative study. J Photochem Photobiol B 80:19–27PubMedCrossRef Pegaz B, Debefve E, Borle F et al (2005) Encapsulation of porphyrins and chlorins in biodegradable nanoparticles: the effect of dye lipophilicity on the extravasation and the photothrombic activity. A comparative study. J Photochem Photobiol B 80:19–27PubMedCrossRef
48.
go back to reference Pegaz B, Debefve E, Borle F et al (2005) Preclinical evaluation of a novel water-soluble chlorin E6 derivative (BLC 1010) as photosensitizer for the closure of the neovessels. Photochem Photobiol 81:1505–1510PubMedCrossRef Pegaz B, Debefve E, Borle F et al (2005) Preclinical evaluation of a novel water-soluble chlorin E6 derivative (BLC 1010) as photosensitizer for the closure of the neovessels. Photochem Photobiol 81:1505–1510PubMedCrossRef
49.
go back to reference Pegaz B, Debefve E, Ballini JP et al (2006) Photothrombic activity of m-THPC-loaded liposomal formulations: pre-clinical assessment on chick chorioallantoic membrane model. Eur J Pharm Sci 28:134–140PubMedCrossRef Pegaz B, Debefve E, Ballini JP et al (2006) Photothrombic activity of m-THPC-loaded liposomal formulations: pre-clinical assessment on chick chorioallantoic membrane model. Eur J Pharm Sci 28:134–140PubMedCrossRef
50.
go back to reference Pegaz B, Debefve E, Ballini JP, Konan-Kouakou YN, van den Bergh H (2006) Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin. J Photochem Photobiol B 85:216–222PubMedCrossRef Pegaz B, Debefve E, Ballini JP, Konan-Kouakou YN, van den Bergh H (2006) Effect of nanoparticle size on the extravasation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin. J Photochem Photobiol B 85:216–222PubMedCrossRef
Metadata
Title
Video monitoring of neovessel occlusion induced by photodynamic therapy with verteporfin (Visudyne®), in the CAM model
Authors
E. Debefve
B. Pegaz
H. van den Bergh
G. Wagnières
N. Lange
J.-P. Ballini
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2008
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-008-9106-4

Other articles of this Issue 3/2008

Angiogenesis 3/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine